Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Multifactorial cardiovascular risk].

I Mahé1, J F Bergmann

  • 1Service de Médecine A, Hôpital Lariboisière, Paris.

Presse Medicale (Paris, France : 1983)
|February 22, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A study protocol for a randomised controlled trial evaluating the safety and efficiency of the YEARS algorithm versus computed tomography pulmonary angiography only for suspected acute pulmonary embolism in patients with cancer: the Hydra Study.

Thrombosis research·2026
Same author

Understanding European patterns of deprescribing antithrombotic medication during end-of-life care in patients with cancer.

Thrombosis research·2024
Same author

[Translation into French and republication of: "Treatment of cancer-associated venous thromboembolism in patients under palliative care"].

La Revue de medecine interne·2024
Same author

[Translation into French and republication of: "Central venous catheter associated upper extremity deep vein thrombosis in cancer patients: Diagnosis and therapeutic management"].

La Revue de medecine interne·2024
Same author

[Translation into French and republication of: "Recurrent venous thromboembolism in anticoagulated cancer patients: diagnosis and treatment"].

La Revue de medecine interne·2024
Same author

[Translation into French and republication of: "Management of cancer-associated thromboembolism in vulnerable population"].

La Revue de medecine interne·2024
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Cardiovascular risk assessment, using tools like the Framingham formula, helps predict heart disease and stroke. While valuable for prevention, it has limitations and doesn't account for all risk factors.

Area of Science:

  • Public Health
  • Epidemiology
  • Cardiology

Context:

  • Cardiovascular diseases (CVD) are a leading cause of mortality globally.
  • CVDs represent a significant portion of healthcare expenditures.
  • Effective risk assessment is crucial for public health strategies.

Purpose:

  • To evaluate the importance of cardiovascular risk assessment.
  • To introduce the Framingham formula as a widely used risk assessment tool.
  • To discuss the benefits and limitations of current risk assessment methods.

Summary:

  • Cardiovascular risk assessment utilizes epidemiological data and individual factors to estimate the likelihood of ischemic heart disease or stroke.
  • The Framingham formula integrates age, sex, blood pressure, smoking, and diabetes status for objective risk estimation.

Related Experiment Videos

  • Despite limitations, including unquantifiable or recent risk factors, the formula is a practical tool for clinicians.

    • Impact:

    • Facilitates therapeutic decision-making and guides primary and secondary prevention strategies.
    • Offers practical and economic advantages in managing individual patient care.
    • Provides a valuable, albeit imperfect, tool for daily clinical practice in cardiovascular disease prevention.